SCHEMBL860313

SCHEMBL860313

COC(=O)c1cccc(-c2ccn3ncc(C=C4SC(=S)NC4=O)c3n2)c1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 2/20 0.47
HSPD1 P10809 1/20 0.44
HSPE1 P61604 1/20 0.44
MTOR P42345 2/20 0.44
RPTOR Q8N122 1/20 0.44
MLST8 Q9BVC4 1/20 0.44
TDP1 Q9NUW8 1/20 0.43
IDH1 O75874 1/20 0.43
PIM1 P11309 3/20 0.41
PIM3 Q86V86 1/20 0.41
PIM2 Q9P1W9 1/20 0.41
NAT1 P18440 3/20 0.41
PDE4B Q07343 1/20 0.41
MAOB P27338 1/20 0.41
CISD1 Q9NZ45 1/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12978788 1.00 PIK3CG (0.47) PIK3CGHSPD1HSPE1MTORRPTOR
SCHEMBL860312 1.00 PIK3CG (0.47) PIK3CGHSPD1HSPE1MTORRPTOR
SCHEMBL12978775 0.91 PIK3CG (0.54) PIK3CGTDP1PIM1PIM2HPGD
SCHEMBL860640 0.91 PIK3CG (0.54) PIK3CGTDP1PIM1PIM2HPGD
SCHEMBL860639 0.91 PIK3CG (0.54) PIK3CGTDP1PIM1PIM2HPGD
SCHEMBL860025 0.81 PIK3CG (0.52) PIK3CGMTORTDP1PIM1PIM3
SCHEMBL860026 0.81 PIK3CG (0.52) PIK3CGMTORTDP1PIM1PIM3
SCHEMBL12978957 0.81 PIK3CG (0.52) PIK3CGMTORTDP1PIM1PIM3
SCHEMBL12769034 0.80 ERN1 (0.51) PIK3CG
SCHEMBL14679081 0.78 GABRG2 (0.37) PIK3CGTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367681-B2 Pyrazolopyrimidines and related heterocycles as kinase inhibitors CYLENE PHARMACEUTICALS, INC. (US) 2013-02-05 US disclosed
EP-2432473-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS Cylene Pharmaceuticals, Inc. (US) 2012-03-28 EP disclosed
US-20100331314-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS SENHWA BIOSCIENCES, INC. (TW) 2010-12-30 US disclosed
WO-2010135581-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS CYLENE PHARMACEUTICALS, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331314-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS PIM1, PIM2, PIM3 PIK3CG 415/4885HSPD1 1881/4885HSPE1 2359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.